JP6208140B2 - キノリン誘導体の調製プロセス - Google Patents

キノリン誘導体の調製プロセス Download PDF

Info

Publication number
JP6208140B2
JP6208140B2 JP2014537359A JP2014537359A JP6208140B2 JP 6208140 B2 JP6208140 B2 JP 6208140B2 JP 2014537359 A JP2014537359 A JP 2014537359A JP 2014537359 A JP2014537359 A JP 2014537359A JP 6208140 B2 JP6208140 B2 JP 6208140B2
Authority
JP
Japan
Prior art keywords
mixture
compound
acid
formula
polar aprotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014537359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530880A (ja
Inventor
ジョー アン ウィルソン，
ジョー アン ウィルソン，
スリラム ナガナサン，
スリラム ナガナサン，
マシュー プファイファー，
マシュー プファイファー，
ニール ジー． アンデルセン，
ニール ジー． アンデルセン，
Original Assignee
エクセリクシス， インク．
エクセリクシス， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセリクシス， インク．, エクセリクシス， インク． filed Critical エクセリクシス， インク．
Publication of JP2014530880A publication Critical patent/JP2014530880A/ja
Application granted granted Critical
Publication of JP6208140B2 publication Critical patent/JP6208140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014537359A 2011-10-20 2012-10-22 キノリン誘導体の調製プロセス Active JP6208140B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549312P 2011-10-20 2011-10-20
US61/549,312 2011-10-20
PCT/US2012/061320 WO2013059788A1 (en) 2011-10-20 2012-10-22 Process for preparing quinoline derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017112355A Division JP2017222648A (ja) 2011-10-20 2017-06-07 キノリン誘導体の調製プロセス

Publications (2)

Publication Number Publication Date
JP2014530880A JP2014530880A (ja) 2014-11-20
JP6208140B2 true JP6208140B2 (ja) 2017-10-04

Family

ID=47146705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014537359A Active JP6208140B2 (ja) 2011-10-20 2012-10-22 キノリン誘導体の調製プロセス
JP2017112355A Pending JP2017222648A (ja) 2011-10-20 2017-06-07 キノリン誘導体の調製プロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017112355A Pending JP2017222648A (ja) 2011-10-20 2017-06-07 キノリン誘導体の調製プロセス

Country Status (23)

Country Link
US (3) US9365516B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2768796B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP6208140B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102075371B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN104395284A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR088483A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2012325768B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014009302B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2852771C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2768796T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA031485B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2765013T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20207110B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE048023T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL232139A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014CN02971A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX343288B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2768796T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2768796T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI642650B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA116876C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013059788A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201402579B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2593090T (pt) 2010-07-16 2021-11-04 Exelixis Inc Composições farmacêuticas moduladoras de c-met
US20140057943A1 (en) 2010-09-27 2014-02-27 Exelixix, Inc. Method of Treating Cancer
AR085155A1 (es) 2011-02-10 2013-09-11 Exelixis Inc Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
US10166225B2 (en) 2011-09-22 2019-01-01 Exelixis, Inc. Method for treating osteoporosis
DK2768796T3 (da) * 2011-10-20 2020-02-24 Exelixis Inc Fremgangsmåde til fremstilling af quinolin-derivater
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP2981263B1 (en) 2013-04-04 2022-06-29 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CN104649969B (zh) * 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
UA123534C2 (uk) 2014-02-14 2021-04-21 Екселіксис, Інк. Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
CA2957466C (en) 2014-08-05 2023-10-17 Exelixis, Inc. Drug combinations to treat multiple myeloma
EP3345894B1 (en) * 2015-09-02 2021-12-29 Chen, Kuenfeng Compound having protein tyrosine phosphatase shp-1 agonist activity
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN109836382B (zh) * 2017-11-29 2021-11-05 江苏豪森药业集团有限公司 苹果酸卡博替尼及其中间体的制备方法
MX2020007765A (es) 2018-01-26 2020-09-25 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.
CN115569137A (zh) 2018-06-15 2023-01-06 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN112142619B (zh) * 2020-10-20 2023-01-10 浙江工业大学 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用
EP4313048A4 (en) * 2021-03-24 2025-01-08 Biocon Limited METHOD FOR THE PREPARATION OF CABOZANTINIB
WO2024111001A1 (en) * 2022-11-25 2024-05-30 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
JP2008537748A (ja) 2005-04-06 2008-09-25 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009136663A1 (en) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
EA019247B1 (ru) 2008-11-13 2014-02-28 Экселиксис, Инк. Способы получения хинолиновых производных
EP2367795A1 (en) 2008-12-04 2011-09-28 Exelixis, Inc. Methods of preparing quinoline derivatives
TWI511956B (zh) * 2009-01-16 2015-12-11 Exelixis Inc 製備ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺之方法
WO2011009095A1 (en) 2009-07-17 2011-01-20 Exelixis, Inc. Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2011224203A1 (en) 2010-03-12 2012-10-04 Exelixis, Inc Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin -4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl] -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009723A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
PT2593090T (pt) 2010-07-16 2021-11-04 Exelixis Inc Composições farmacêuticas moduladoras de c-met
US20140057943A1 (en) 2010-09-27 2014-02-27 Exelixix, Inc. Method of Treating Cancer
JP2013540759A (ja) 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
AR085155A1 (es) 2011-02-10 2013-09-11 Exelixis Inc Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US10166225B2 (en) 2011-09-22 2019-01-01 Exelixis, Inc. Method for treating osteoporosis
DK2768796T3 (da) * 2011-10-20 2020-02-24 Exelixis Inc Fremgangsmåde til fremstilling af quinolin-derivater
US20140323522A1 (en) 2011-11-08 2014-10-30 Exelixis, Inc. Method of Treating Cancer
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス， インク． 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤

Also Published As

Publication number Publication date
BR112014009302B1 (pt) 2020-04-28
AU2012325768B2 (en) 2017-08-10
NZ624328A (en) 2016-10-28
MX2014004583A (es) 2014-10-06
US9365516B2 (en) 2016-06-14
TW201321342A (zh) 2013-06-01
EP2768796A1 (en) 2014-08-27
US9969692B2 (en) 2018-05-15
PT2768796T (pt) 2020-02-21
ES2765013T3 (es) 2020-06-05
BR112014009302A2 (pt) 2017-05-23
TWI642650B (zh) 2018-12-01
CA2852771A1 (en) 2013-04-25
EA201490831A1 (ru) 2014-09-30
EP2768796B1 (en) 2019-11-20
ZA201402579B (en) 2015-03-25
AU2012325768A1 (en) 2014-05-22
CN110511158A (zh) 2019-11-29
US20180230100A1 (en) 2018-08-16
HUE048023T2 (hu) 2020-05-28
AU2017254982A1 (en) 2017-11-23
HK1201517A1 (en) 2015-09-04
GEP20207110B (en) 2020-05-25
GEAP201913471A (en) 2019-10-25
DK2768796T3 (da) 2020-02-24
TW201731812A (zh) 2017-09-16
AR088483A1 (es) 2014-06-11
NZ723880A (en) 2018-03-23
MX343288B (es) 2016-11-01
US20140256938A1 (en) 2014-09-11
TWI619694B (zh) 2018-04-01
WO2013059788A1 (en) 2013-04-25
US20160229805A1 (en) 2016-08-11
KR102075371B1 (ko) 2020-02-10
IN2014CN02971A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-03
IL232139A0 (en) 2014-05-28
CN104395284A (zh) 2015-03-04
EA031485B1 (ru) 2019-01-31
UA116876C2 (uk) 2018-05-25
KR20140088874A (ko) 2014-07-11
JP2014530880A (ja) 2014-11-20
PL2768796T3 (pl) 2020-05-18
JP2017222648A (ja) 2017-12-21
IL232139A (en) 2017-11-30
CA2852771C (en) 2019-11-26

Similar Documents

Publication Publication Date Title
JP6208140B2 (ja) キノリン誘導体の調製プロセス
JP6513598B2 (ja) キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法
KR20120051702A (ko) Ｎ-〔３-플루오로-４-(｛６-(메틸옥시)-７-〔(３-모르폴린-４-일프로필)옥시〕퀴놀린-４-일｝옥시)페닐〕-ｎ''-(４-플루오로페닐)시클로프로판-１,１-디카르복사미드의 결정형
CN102388024A (zh) N-(4-{[6,7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺的苹果酸盐及其用于癌症治疗的结晶型
US20100087459A1 (en) Forms of lapatinib compounds and processes for the preparation thereof
WO2016101867A1 (zh) 萘普替尼对甲苯磺酸盐的α晶型及制备方法和含有其的药物组合物
WO2025002355A9 (zh) 一种jak2抑制剂的晶型及制备方法
NZ723880B2 (en) Process for preparing quinoline derivatives
NZ624328B2 (en) Process for preparing quinoline derivatives
HK1201517B (en) Process for preparing quinoline derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170906

R150 Certificate of patent or registration of utility model

Ref document number: 6208140

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250